Primeri uporabe Should not be used in patients v Angleški in njihovi prevodi v Slovenski
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
The device should not be used in patients who.
Reyataz should be used withcaution in patients with mild liver problems, and should not be used in patients with moderate or severe liver problems.
Zdravilo Reyataz je treba Synjardy should not be used in patients with type 1 diabetes.
Treatment of UA/ NSTEMI and STEMI- fondaparinux should not be used in patients with creatinine clearance< 20 ml/ min(see section 4.3).
Zdravljenje UA/ NSTEMI in STEMI- Fondaparinuksa se ne sme uporabljati pri bolnikih s kreatininskim očistkom< 20 ml/ min(glejte poglavje 4. 3).Inovelon should not be used in patients who have severe problems with their liver.
Zdravila Inovelon ne smejo jemati bolniki s hudimi težavami z jetri.
Ljudje tudi prevajajo
Treatment of superficial-vein thrombosis- Fondaparinux should not be used in patients with creatinine clearance< 20 ml/min(see section 4.3).
Zdravljenje povrhnje venske tromboze- Fondaparinuksa se ne sme uporabljati pri bolnikih z očistkom kreatinina< 20 ml/min(glejte poglavje 4.3).Ariclaim should not be used in patients with certain types of liver disease or with severe kidney disease.
Zdravila Ariclaim ne sme uporabljati bolnikih z določenimi obolenji jeter ali s hudim obolenjem ledvic.Consequently, Enbrel should not be used in patients for the treatment of alcoholic hepatitis.
Zato zdravila LIFMIOR ne smemo uporabljati pri bolnikih za zdravljenje alkoholnega hepatitisa.AZILECT should not be used in patients who have severe problems with their liver.
Zdravila AZILECT ne smejo uporabljati bolniki, ki imajo hude težave z jetri.Jentadueto should not be used in patients with type 1 diabetes.
The medicine should not be used in patients who have severe problems with their liver or their kidneys.
Zdravila ne smejo jemati bolniki, ki imajo hude težave z jetri ali ledvicami.Riluzole Zentiva should not be used in patients with any other form of motor neurone disease.
Zdravilo Riluzole Zentiva se ne sme uporabljati pri bolnikih z drugimi oblikami bolezni motoričnega nevrona.REYATAZ should not be used in patients with moderate to severe hepatic impairment(see sections 4.3, 4.4, and 5.2).
Zdravila REYATAZ se ne sme uporabljati pri bolnikih z zmerno do hudo okvaro jeter(glejte poglavja 4. 3, 4. 4 in 5. 2).Signifor should not be used in patients with severe hepatic impairment(Child Pugh C)(see sections 4.3 and 4.4).
Zdravila Signifor se ne sme uporabljati pri bolnikih s hudo okvaro jeter(Child Pugh stopnje C)(glejte poglavji 4.3 in 4.4).Exviera should not be used in patients with severe hepatic impairment(Child-Pugh C)(see sections 4.2, 4.8 and 5.2).
Zdravilo Exviera se ne sme uporabljati pri bolnikih s hudo okvaro jeter(Child-Pugh C)(glejte poglavja 4.2, 4.8 in 5.2.).Extavia should not be used in patients who are currently suffering from severe depression and/ or have thoughts of suicide.
Zdravila Extavia prav tako ne smejo uporabljati bolniki, ki trpijo za depresijo in/ ali imajo samomorilne misli.RILUTEK should not be used in patients who have liver disease or who have abnormally high levels of liver enzymes.
Zdravila RILUTEK ne bi smeli uporabljati bolniki z boleznimi jeter ali Eucreas should not be used in patients who have moderate or severe problems with their kidneys or who have problems with their liver.
Zdravila Eucreas se ne sme uporabljati pri bolnikih, ki imajo zmerne ali hude težave z ledvicami ali imajo težave z jetri.Extavia should not be used in patients who have decompensated liver disease(when the liver does not function normally).
Zdravila Extavia ne smejo uporabljati bolniki z dekompenzirano boleznijo jeter(pri kateri jetra ARICLAIM should not be used in patients with severe renal impairment(creatinine clearance< 30 ml/ min; see section 4.3).
Zdravila ARICLAIM ne smemo uporabljati pri bolnikih s hudo okvarjenim delovanjem ledvic(očistek kreatinina< 30 ml/ min; glejte poglavje 4. 3).Tandemact should not be used in patients with severe renal function disorders(creatinine clearance< 30 ml/ min, see section 4.3).
Tandemact se ne sme uporabljati pri bolnikih s hudo motnjo ledvičnega delovanja(očistek kreatinina< 30 ml/ min, glejte poglavje 4. 3).Tasmar should not be used in patients who may be hypersensitive(allergic) to tolcapone or any of the other ingredients.
Zdravila Tasmar ne smejo uporabljati bolniki, ki utegnejo biti preobčutljivi za(alergični na) tolkapon ali katerokoli drugo sestavino zdravila.InductOs should not be used in patients with history or clinical suspicion of malignancy at the site of application(see section 4.3).
Zdravilo InductOs se ne sme uporabljati pri bolnikih z anamnezo ali kliničnim sumom na maligno bolezen na mestu uporabe(glejte poglavje 4.3).ARICLAIM should not be used in patients with liver disease resulting in hepatic impairment(see section 4.3).
Okvarjeno delovanje jeter Zdravila ARICLAIM ne smemo uporabljati pri bolnikih z obolenjem jeter, katerega posledica je okvarjeno delovanje jeter(glejte poglavje 4. 3).Velmetia should not be used in patients with moderate or severe renal impairment(creatinine clearance< 60 mL/min)(see sections 4.3 and 4.4).
Zdravila Velmetia se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro(kreatininski očistek< 60 ml/min)(glejte poglavji 4.3 in 4.4).Competact should not be used in patients with renal failure or renal dysfunction(creatinine clearance< 60 ml/min)(see sections 4.3 and 4.4).
Zdravilo Competact se ne sme uporabljati pri bolnikih z ledvično odpovedjo ali ledvično disfunkcijo(očistek kreatinina< 60 ml/min)(glejte poglavji 4.3 in 4.4).Imprida should not be used in patients who have severe liver, kidney or bile problems, or in patients undergoing dialysis(a blood clearance technique).
Zdravila Imprida prav tako ne smejo jemati bolniki, ki imajo hude težave z jetri, ledvicami ali izločanjem žolča, ali Raloxifene should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Raloksifena ne bi smeli uporabljati pri bolnicah, ki kažejo znake ali simptome raka endometrija, saj varnost zdravila 
